Pulmonary Arterial Hypertension

Macitentan Not Superior to Placebo for Improving Exercise Capacity in Eisenmenger Syndrome

Macitentan Not Superior to Placebo for Improving Exercise Capacity in Eisenmenger Syndrome

By

Macitentan did not show superiority over placebo for change in exercise capacity in patients with Eisenmenger syndrome.

Treprostinil May Have Antithrombotic Effect in Pediatric Pulmonary Hypertension

Treprostinil May Have Antithrombotic Effect in Pediatric Pulmonary Hypertension

By

Treatment with treprostinil has demonstrated potential antithrombotic mechanisms of action in pediatric patients with pulmonary arterial hypertension.

PAH Survival May Increase Risk for Pulmonary Artery Aneurysms

PAH Survival May Increase Risk for Pulmonary Artery Aneurysms

The time course of pulmonary arterial hypertension was an independent risk factor for pulmonary artery aneurysms.

Societies Publish Appropriate Use Criteria for Multimodality Imaging in Nonvalvular Heart Disease

Societies Publish Appropriate Use Criteria for Multimodality Imaging in Nonvalvular Heart Disease

By

Updated appropriate use criteria addresses the use of multimodality imaging for evaluation of cardiac structure and function in nonvalvular heart disease.

Prognostic Relevance of Cardiopulmonary Exercise Testing in Low-Risk Pulmonary Arterial Hypertension

Prognostic Relevance of Cardiopulmonary Exercise Testing in Low-Risk Pulmonary Arterial Hypertension

By

Combinations of VO2 and change in CI during follow-up visits are valuable prognosis markers in low-risk patients with PAH.

Exercise Capacity in CTEPH Improved With Treprostinil

Exercise Capacity in CTEPH Improved With Treprostinil

By

Compared with the low dose, high-dose subcutaneous treprostinil increased 6-minute walk distances in patients with chronic thromboembolic pulmonary hypertension.

PAH: An Under-Recognized Complication of Adult-Onset Still's Disease

PAH: An Under-Recognized Complication of Adult-Onset Still's Disease

By

PAH is an under-diagnosed complication of adult-onset Still disease.

Comorbid Mental Disorder Prevalence Higher in Pulmonary Arterial Hypertension

Comorbid Mental Disorder Prevalence Higher in Pulmonary Arterial Hypertension

By

People with pulmonary arterial hypertension display higher levels of depression and anxiety than previously estimated by healthcare workers.

Orenitram Decreased Risk of Morbidity/Mortality Event in PAH Trial

Orenitram Decreased Risk of Morbidity/Mortality Event in PAH Trial

By

FREEDOM-EV was an international, multicenter, randomized, double-blind, placebo-controlled trial (N=690) that randomized patients to 3 daily doses of Orenitram or placebo.

Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

By

Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is indicated to treat pulmonary arterial hypertension to improve exercise ability.

Implantable System for Remodulin Approved for Patients With PAH

Implantable System for Remodulin Approved for Patients With PAH

By

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension.

Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes

Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes

By

Current research suggests patients with pulmonary arterial hypertension may benefit from iron and vitamin D supplementation.

PAH Mortality Rates Comparable With ERA or PDE5 Inhibitor Therapy

PAH Mortality Rates Comparable With ERA or PDE5 Inhibitor Therapy

By

There were no significant differences in pulmonary arterial hypertension survival based on therapy type, age was an important modifier.

Pulmonary Arterial Stiffness Related to mPAP and Heart Rate in Idiopathic PAH

Pulmonary Arterial Stiffness Related to mPAP and Heart Rate in Idiopathic PAH

By

Pulmonary arterial stiffness was related to mean pulmonary arterial pressure and heart rate in patients with untreated idiopathic pulmonary arterial hypertension.

RV Base/Apex Ratio May Help Diagnose Pulmonary Arterial Hypertension in Children

RV Base/Apex Ratio May Help Diagnose Pulmonary Arterial Hypertension in Children

By

Right ventricular base/apex ratio reference values may help clinicians diagnose children with pulmonary arterial hypertension.

Improved Counseling Needed in Pregnant Patients With Pulmonary Arterial Hypertension

Improved Counseling Needed in Pregnant Patients With Pulmonary Arterial Hypertension

By

Many healthcare providers reported that they often do not have the time to counsel their patients with pulmonary arterial hypertension on pregnancy risks.

PAH in Congenital Heart Disease: Expert Q&A on Challenges and Advances

PAH in Congenital Heart Disease: Expert Q&A on Challenges and Advances

By

Management strategies were discussed for subtypes of PAH-congenital heart disease including Eisenmenger syndrome, PAH with persistent systemic to pulmonary shunts, and PAH with small or coincidental defect or PAH after defect closure.

Improving Risk Stratification, Diagnostic Accuracy in PAH With Cardiopulmonary Exercise Testing

Improving Risk Stratification, Diagnostic Accuracy in PAH With Cardiopulmonary Exercise Testing

By

Cardiopulmonary exercise testing can be an important diagnostic and prognostic tool in pulmonary arterial hypertension.

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

By

There was no significant difference in efficacy between sildenafil and bosentan initial combination therapy and sildenafil monotherapy in patients with systemic sclerosis-related pulmonary arterial hypertension.

Arrhythmia Associated With Higher Mortality in Congenital Heart Disease-Related PAH

Arrhythmia Associated With Higher Mortality in Congenital Heart Disease-Related PAH

By

Arrhythmia was a significant predictor of mortality in adult patients with congenital heart disease and pulmonary arterial hypertension.

Brain Natriuretic Peptide Shows Promise as Biomarker in Group 1 PAH

Brain Natriuretic Peptide Shows Promise as Biomarker in Group 1 PAH

By

There was a significant relationship between brain natriuretic peptide levels and mortality in patients with group 1 pulmonary arterial hypertension.

Connective Tissue Diseases in Comorbid PAH: A Case for Separating SSc, SLE

Connective Tissue Diseases in Comorbid PAH: A Case for Separating SSc, SLE

By

Recent evidence suggests that systemic sclerosis and systemic lupus erythematosus comorbid with pulmonary arterial hypertension should be considered separate diseases.

Pulmonary Hypertension Has Adverse Effect on Post-Lung Transplant Survival

Pulmonary Hypertension Has Adverse Effect on Post-Lung Transplant Survival

By

The 1-year survival rate after lung transplantation in patients with a mean pulmonary arterial pressure ≥25 mm Hg was lower than the survival rate of those with a mean pulmonary arterial pressure <25 mm Hg.

Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

By

The use of a risk calculator aimed at achieving a low-risk profile in PAH trials is discussed.

PAH Risk, Mortality Increased by Disturbances in Male Sex Hormones

PAH Risk, Mortality Increased by Disturbances in Male Sex Hormones

By

Men with higher estradiol and estradiol/testosterone levels had an increased risk for pulmonary arterial hypertension.

AHA: Right-Sided Heart Failure Evaluation, Management Guidelines

AHA: Right-Sided Heart Failure Evaluation, Management Guidelines

By

The American Heart Association scientific statement offers recommendations on right-sided heart failure regarding physical examination, serum markers, and imaging.

Serum Chloride Linked With Survival in Pulmonary Arterial Hypertension

Serum Chloride Linked With Survival in Pulmonary Arterial Hypertension

By

Serum chloride was a strong and independent predictor of mortality at 6 months after a pulmonary arterial hypertension diagnosis.

Predictive Value of Idiopathic PAH Risk Assessment Using Comorbidities, Age

Predictive Value of Idiopathic PAH Risk Assessment Using Comorbidities, Age

By

Ischemic heart disease and kidney dysfunction were identified as 2 comorbidities that may affect outcomes in idiopathic pulmonary arterial hypertension.

Stem Cell Therapy for RV Failure in PAH: Overview and Clinician Interview

Stem Cell Therapy for RV Failure in PAH: Overview and Clinician Interview

By

Stem cell therapy targeting right ventricular failure may help improve pulmonary circulation in pulmonary arterial hypertension.

Opsumit sNDA Submitted for Chronic Thromboembolic Pulmonary Hypertension

Opsumit sNDA Submitted for Chronic Thromboembolic Pulmonary Hypertension

By

The sNDA is accompanied by results from the MERIT-1 trial, a Phase 2 randomized, placebo-controlled, double-blind study which assessed the efficacy, safety and tolerability of macitentan 10mg in 80 patients with inoperable CTEPH.

Sign Up for Free e-Newsletters